Large Absolute Benefit of PCSK9 Inhibition in ACS With Polyvascular Disease - Endocrinology Advisor

Large Absolute Benefit of PCSK9 Inhibition in ACS With Polyvascular Disease  Endocrinology Advisor

Polyvascular disease is associated with high risks of major adverse cardiovascular events and death despite intensive statin therapy.



Comments

Post a Comment

Popular posts from this blog

Orchestra BioMed™ Announces FDA Breakthrough Device Designation for Virtue® Sirolimus-Eluting Balloon for Treatment of Below-the-Knee Peripheral Artery Disease - Vascular Disease Management

Orchestra BioMed™ Announces FDA Breakthrough Device Designation for Virtue® Sirolimus-Eluting Balloon for Treatment of Below-the-Knee Peripheral Artery Disease    Vascular Disease Management First and only non-coated sirolimus-eluting angioplasty balloon system to receive Breakthrough Device designation for below-the-knee disease; Follows ...
Read more